News Release

Printer Friendly Version  View printer-friendly version
<< Back
Neuronetics Reports First Quarter 2019 Financial and Operating Results

MALVERN, Pa., May 07, 2019 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced its financial and operating results for the first quarter of 2019.

First Quarter 2019 Highlights

  • First quarter 2019 revenue of $12.7 million, an increase of 25% over the first quarter of 2018
  • First quarter 2019 U.S. treatment session revenue of $8.8 million, an increase of 21% over the first quarter of 2018
  • First quarter 2019 U.S. NeuroStar® Advanced Therapy revenue of $3.4 million, an increase of 41% over the first quarter of 2018

First Quarter Financial and Operating Results

“During the first quarter, we continued to execute on our strategy to drive the adoption of NeuroStar Advanced Therapy, which resulted in strong system sales growth and total revenue in line with our expectations,” said Chris Thatcher, President and Chief Executive Officer of Neuronetics.  “Looking to the balance of the year, in addition to our efforts to generate an increased number of treatment sessions from our expanded installed base of NeuroStar Advanced Therapy Systems, we plan to continue to drive growth through the expansion of our salesforce, the effective use of marketing initiatives, and the commercialization in Japan following reimbursement approval.”

    Revenues by Geography
    Three Months ended March 31,
      2019     2018    
    Amount   Amount   % Change
    (in thousands, except percentages)
United States   $ 12,546   $ 9,972   26 %
International     182     180   1 %
Total revenues   $ 12,728   $ 10,152   25 %


    United States Revenues by Product Category  
    Three Months ended March 31,  
    2019   2018      
    Amount   Amount   % Change  
    (in thousands, except percentages)  
NeuroStar Advanced Therapy System   $ 3,350   $ 2,373   41 %
Treatment sessions     8,778     7,240   21 %
Other     418     359   16 %
Total United States revenues   $ 12,546   $ 9,972   26 %

U.S. NeuroStar Advanced Therapy revenue for the first quarter of 2019 was $3.4 million, an increase of 41% over first quarter 2018 revenue of $2.4 million. The increase in U.S. NeuroStar Advanced Therapy System revenue was primarily driven by higher capital and rent-to-own revenue.  Capital units sold increased by 42% and average selling prices declined by 8% as compared to last year. On a sequential quarterly basis, average selling prices for capital sales were up approximately one-half of a percentage point.

As of March 31, 2019, the active unit installed base in the U.S. was 931. This represents an increase of  24 units over the active unit installed base as of December 31, 2018, and an increase of 150 units over the active unit installed base as of March 31, 2018.

U.S. Treatment Session revenue for the first quarter of 2019 was $8.8 million, an increase of 21% over first quarter of 2018 revenue of $7.2 million. The increase in U.S. Treatment Session revenue was primarily the result of an 18% increase in the number of treatment sessions sold, partially offset by a 3% decline in average selling price due to pre-determined volume pricing discounts within our existing customer base, which are triggered when those customers surpass certain high-volume thresholds, plus an increase in other treatment session revenue. 

Gross margin for the first quarter of 2019 was 77.9%, which was higher than the first quarter of 2018 gross margin of 75.8%. The majority of the increase in gross margin was the result of increased leverage on our service and operations costs as a result of higher sales compared to the prior year period.

Operating expenses during the first quarter of 2019 were $17.0 million, an increase of $4.7 million compared to $12.3 million in the first quarter of 2018. The increase was primarily driven by sales force expansion and marketing initiatives, higher product and clinical development expenses, as well as additional general and administrative expenses incurred to report as a public company.

Net loss for the first quarter of 2019 was $7.5 million, or $0.42 per share, as compared to first quarter 2018 net loss of $5.5 million, or $24.43 per share. Net loss per share for the first quarter of 2019 is calculated on a weighted-average basis, and includes the 11.0 million shares of common stock issued upon the conversion of convertible preferred stock and 6.325 million shares of common stock issued at the closing of our initial public offering.   There were 18.227 million shares of common stock outstanding as of March 31, 2019.

EBITDA for the first quarter of 2019 was $(6.4) million as compared to the first quarter of 2018 EBITDA of $(4.4) million. See the accompanying financial table that reconciles EBITDA, which is a non-GAAP measure, to net loss.

Cash and cash equivalents were $96.1 million as of March 31, 2019. This compares to cash and cash equivalents of $104.6 million as of December 31, 2018.

Business Outlook

For the second quarter of 2019, the Company expects total worldwide revenue of between $15.6 and $16.2 million, representing 18% and 22% year-over-year growth, respectively.

For the full year 2019, the Company expects to report total worldwide revenue of between $62.5 and $64.5 million, representing 18% and 22% year-over-year growth, respectively.

For the full year 2019, the Company expects gross margins to be in the mid 70% range, in line with full year 2018 margins.

For the full year 2019, the Company expects operating expenses to be between $71.5 and $76.5 million, primarily due to continued investment in our salesforce expansion efforts, research and development related to the development of our next generation NeuroStar platform and clinical spending as we pursue additional indications for use, namely PTSD and Bi-Polar disorders. 

Webcast and Conference Call Information

Neuronetics’ management team will host a conference call on May 7, 2019 beginning at 8:30 a.m.  Eastern Time.  Investors interested in listening to the conference call may do so by dialing (877) 472-8990 for domestic callers or +1 (629) 228-0778 for international callers, and referencing Conference ID: 3888389 approximately 10 minutes prior to start time.  To access the live audio webcast or subsequent archived recording, visit the Investor Relations section of Neuronetics’ website at www.neuronetics.com.

About Neuronetics

Neuronetics, Inc. is a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Our first commercial product, the NeuroStar® Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood.  The system is cleared by the United States Food and Drug Administration, or FDA, for the treatment of major depressive disorder in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode.  Additional information can be found at www.neuronetics.com.

“Safe harbor” statement under the Private Securities Litigation Reform Act of 1995

Statements in the press release regarding Neuronetics, Inc. (the “Company”) that are not historical facts constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may be identified by terms such as “outlook,” “potential,” “believe,” “expect,” “plan,” “anticipate,” “predict,” “may,” “will,” “could,” “would” and “should” as well as the negative of these terms and similar expressions. These statements include those relating to: the Company’s business outlook and current expectations for upcoming quarter and fiscal year, including with respect to any specific projections provided; the Company’s expectations regarding growth opportunities and the build out of its NeuroStar Advanced Therapy System platform; expectations or beliefs regarding future events, potential markets or market size, and technological developments; and any statements of assumptions underlying any of the foregoing items. These statements are subject to significant risks and uncertainties and actual results could differ materially from those projected. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this release. These risks and uncertainties include, without limitation, risks and uncertainties related to: the Company’s ability to achieve or sustain profitable operations due to its history of losses; the Company’s reliance on the sale and usage of its NeuroStar Advanced Therapy System to generate revenues; availability and extent of coverage and reimbursement from third-party payors for treatments using the Company’s products; physician and patient demand for treatments using the Company’s products; developments in respect of competing technologies and therapies for the indications that the Company’s products treat; product defects; the Company’s ability to obtain and maintain intellectual property protection for its technology; and developments in regulation in the United States and other applicable jurisdictions. For a discussion of these and other related risks, please refer to the Company’s recent SEC filings which are available on the SEC’s website at  www.sec.gov.  These forward-looking statements are based on the Company's expectations and assumptions as of the date of this press release. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events or changes in the Company's expectations.

Investor Contact:

Mark R. Klausner
Westwicke Partners
443-213-0501
ir@neuronetics.com

Media Contact:

Leanne Scott Brown
Vault Communications
610-455-2742
Lbrown@vaultcommunications.com

NEURONETICS, INC.
Statements of Operations
(Unaudited; In thousands, except per share data)

    Three Months ended
March 31,
 
    2019     2018  
Revenues   $ 12,728     $ 10,152  
Cost of revenues     2,807       2,457  
   Gross Profit     9,921       7,695  
Operating expenses:                
Sales and marketing     9,592       8,109  
General and administrative     4,599       2,636  
Research and development     2,786       1,555  
Total operating expenses     16,977       12,300  
   Loss from Operations     (7,056 )     (4,605 )
Other (income) expense:                
Interest expense     919       921  
Other expense (income), net     (446 )     (29 )
   Net Loss   $ (7,529 )   $ (5,497 )
                 
Net loss per share of common stock outstanding, basic and diluted   $ (0.42 )   $ 24.43  
Weighted-average common shares outstanding, basic and diluted     18,026       226  


NEURONETICS, INC.
Balance Sheets
(Unaudited; In thousands, except per share data)

    March 31,     December 31,  
    2019     2018  
Assets                
Current assets:                
Cash and cash equivalents   $ 96,146     $ 104,583  
Accounts receivable, net     5,666       5,620  
Inventory     2,410       2,432  
Current portion of net investments in sales-type leases     135       -  
Current portion of prepaid commission expense     59       -  
Prepaid expenses and other current assets     1,627       1,838  
Total current assets     106,043       114,473  
Property and equipment, net     1,210       1,378  
Operating lease right-of-use assets     4,113       -  
Net investments in sales-type leases     225       -  
Prepaid commission expense     456       -  
Other assets     1,390       1,171  
Total Assets   $ 113,437     $ 117,022  
Liabilities and Stockholders Equity                
Current liabilities:                
Accounts payable   $ 2,588     $ 3,756  
Accrued expenses     6,291       7,548  
Deferred revenue     2,467       2,255  
Current portion of operating lease liabilities     515       -  
Total current liabilities     11,861       13,559  
Long-term debt, net     30,572       30,395  
Deferred revenue     1,849       1,940  
Operating lease liabilities     3,734       -  
Deferred rent     -       86  
Total Liabilities     48,016       45,980  
Stockholders’ Equity :                
Preferred stock, $0.01 par value: 10,000 shares authorized; no shares
  issued or outstanding at March 31, 2019 and December 31, 2018
    -       -  
Common stock, $0.01 par value: 200,000 shares authorized; 18,227 and
  17,744 shares issued and outstanding at March 31, 2019 and December 31, 2018, respectively
    182       177  
Additional paid-in capital     293,811       291,908  
Accumulated deficit     (228,572 )     (221,043 )
Total Stockholders' Equity     65,421       71,042  
Total Liabilities and Stockholders’ Equity   $ 113,437     $ 117,022  


NEURONETICS, INC.
Statements of Cash Flows
(Unaudited; In thousands)

    Three Months ended
March 31,
 
    2019     2018  
Cash Flows from Operating Activities:                
Net loss   $ (7,529 )   $ (5,497 )
Adjustments to reconcile net loss to net cash used in operating activities:                
Depreciation and amortization     204       139  
Share-based compensation     501       144  
Non-cash interest expense     177       247  
Change in fair value of convertible preferred stock warrant liability     -       7  
Cost of rental units purchased by customers     27       66  
Changes in certain assets and liabilities:                
   Accounts receivable, net     (47 )     (15 )
   Inventory     59       (298 )
   Net investment in sales-type leases     (360 )     -  
   Prepaid commission expense     (515 )     -  
   Prepaid expenses and other assets     504       219  
   Accounts payable     (1,475 )     263  
   Accrued expenses     (1,236 )     (3,106 )
   Deferred revenue     120       (453 )
   Deferred rent     -       (13 )
      Net Cash Used in Operating Activities     (9,570 )     (8,297 )
Cash Flows from Investing Activities:                
Purchases of property and equipment and capitalized software     (274 )     (297 )
      Net Cash Used in Investing Activities     (274 )     (297 )
Cash Flows from Financing Activities:                
Payments of public offering costs     -       (230 )
Proceeds from exercises of stock options     1,407       31  
      Net Cash Provided by (Used in) Financing Activities     1,407       (199 )
      Net (Decrease) in Cash and Cash Equivalents     (8,437 )     (8,793 )
      Cash and Cash Equivalents, Beginning of Period     104,583       29,147  
      Cash and Cash Equivalents, End of Period   $ 96,146     $ 20,354  

Non-GAAP Measures

EBITDA is not a measure of financial performance under United States generally accepted accounting principles, or GAAP, and should not be construed as a substitute for, or superior to, GAAP net loss. However, management uses both the GAAP and non-GAAP financial measures internally to evaluate and manage the Company’s operations and to better understand its business. Further, management believes the addition of the non-GAAP financial measure provides meaningful supplementary information to, and facilitates analysis by, investors in evaluating the Company’s financial performance, results of operations and trends. The Company’s calculation of EBITDA may not be comparable to similarly designated measures reported by other companies, since companies and investors may differ as to what type of events warrant adjustment.

The following table reconciles reported net loss to EBITDA:

    Three Months ended
March 31,
 
    2019     2018  
EBITDA Reconciliation   (in thousands)  
Net loss   $ (7,529 )   $ (5,497 )
Interest expense     919       921  
Income taxes     -       -  
Depreciation and amortization     204       139  
EBITDA   $ (6,406 )   $ (4,437 )

 

NEURONETICS_logo high res.jpg

Neuronetics